caa a22 4500 475833554 CHVBK 20180406123847.0 cr unu---uuuuu 170329e20000301xx s 000 0 eng 10.1023/A:1007886725480 doi (NATIONALLICENCE)springer-10.1023/A:1007886725480 Endothelial Dysfunction in Hypercholesterolemia is Reversed by a Nutritional Product Designed to Enhance Nitric Oxide Activity [Elektronische Daten] [Andrew Maxwell, Barbara Anderson, Michael Zapien, John Cooke] The objective of this study was to investigate the vascular andbiochemical effects of a formulated product in the form of a bar enrichedwith a combination of nutrients known to enhance the synthesis oractivity of endothelium-derived nitric oxide (EDNO). Individuals withhypercholesterolemia manifest impaired flow-mediated vasodilation, which islargely due to a reduction in EDNO activity. Oral supplementation withlarge amounts (6-21 g/day) of L-arginine, the precursor of EDNO,have been shown to improve endothelium-mediated vasodilation inhypercholesterolemia. Such large doses are effective but may be impracticalto take in capsule form. Accordingly, we have developed a nutrient barenriched with L-arginine as well as other ingredients that additivelyenhance EDNO activity. A pilot study in 41 hypercholesterolemic individualsindicated that the bar was well tolerated, had no adverse effects on serumchemistries or lipid profile, and normalized endothelial vasodilatorfunction. To definitively determine if the nutrient bar normalizesendothelial function, a double-blind, placebo-controlled study wasperformed. Flow-mediated endothelium-dependent vasodilation was assessedby high-resolution ultrasonography before and after 1 week of bar use(2 bars/day) in an additional group of 43 volunteer subjects (57 ±10 years old; 22 men, 21 women) with hypercholesterolemia. Subjectsmanifested an impaired flow-mediated vasodilation before theintervention. Vasodilator function in the active bar group improved towithin a normal range (6.5 ± 3% before to10 ± 5% after, P = 0.02; normal, 12± 3%) and was significantly better (P < 0.01)than in the placebo bar group (7.1 ± 3% before to6.7 ± 4% after). These findings reveal that use of a nutrientbar designed to enhance EDNO activity improves flow-mediatedendothelium-dependent vasodilation in hypercholesterolemicindividuals. Kluwer Academic Publishers, 2000 L-arginine nationallicence hypercholesterolemia nationallicence atherosclerosis nationallicence blood flow nationallicence nitric oxide nationallicence vasoconstriction/dilation nationallicence endothelial function nationallicence Maxwell Andrew Cooke Pharma, Inc., Belmont, California aut Anderson Barbara Cooke Pharma, Inc., Belmont, California aut Zapien Michael Cooke Pharma, Inc., Belmont, California aut Cooke John Division of Cardiovascular Medicine, Stanford University, Palo Alto, California, USA aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/3(2000-03-01), 309-316 0920-3206 14:3<309 2000 14 10557 https://doi.org/10.1023/A:1007886725480 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007886725480 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Maxwell Andrew Cooke Pharma, Inc., Belmont, California aut NATIONALLICENCE 700 1- Anderson Barbara Cooke Pharma, Inc., Belmont, California aut NATIONALLICENCE 700 1- Zapien Michael Cooke Pharma, Inc., Belmont, California aut NATIONALLICENCE 700 1- Cooke John Division of Cardiovascular Medicine, Stanford University, Palo Alto, California, USA aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/3(2000-03-01), 309-316 0920-3206 14:3<309 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer